Aptamer Targets Triple-Negative Breast Cancer through Specific Binding to Surface CD49c

Aptamer Targets Triple-Negative Breast Cancer through Specific Binding to Surface CD49c

Although targeted cancer therapy can induce higher therapeutic efficacy and cause fewer side effects in patients, the lack of targetable biomarkers on triple-negative breast cancer (TNBC) cells limits the development of targeted therapies by antibody technology. Therefore, we investigated an alterna...

Full description

Bibliographic Details
Main Authors: Quanyuan Wan, Zihua Zeng, Jianjun Qi, Yingxin Zhao, Xiaohui Liu, Zhenghu Chen, Haijun Zhou, Youli Zu
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Cancers
Subjects:
aptamer ligand
biomarker identification
integrin α3/CD49c
triple-negative breast cancer (TNBC)
targeted cancer therapy
Online Access:https://www.mdpi.com/2072-6694/14/6/1570

Internet

https://www.mdpi.com/2072-6694/14/6/1570

Similar Items